Question 1

The peripheral blood smear in DIC resembles that of:

Accepted Answer

A)  Iron-deficiency anemia 
B)  Microangiopathic hemolytic anemia 
C)  Hemoglobin C disease 
D)  Megaloblastic anemia 
E)  None of the above 
A)  Iron-deficiency anemia 
B)  Microangiopathic hemolytic anemia 
C)  Hemoglobin C disease 
D)  Megaloblastic anemia 
E)  None of the above

Question 2

The primary physiologic inhibitor of plasmin in-vivo is __________.

Accepted Answer

A)  C1 inactivator 
B)  AT-III 
C)  α2-Anti-plasmin inhibitor 
D)  α2-Antitrypsin 
E)  None of the above 
A)  C1 inactivator 
B)  AT-III 
C)  α2-Anti-plasmin inhibitor 
D)  α2-Antitrypsin 
E)  None of the above

Question 3

Which of the following are laboratory tests to detect the action of plasmin on fibrin/fibrinogen?

Accepted Answer

A)  D-dimer assay 
B)  Euglobulin test 
C)  Level of plasminogen in plasma 
D)  FDPs 
E)  All of the above 
A)  D-dimer assay 
B)  Euglobulin test 
C)  Level of plasminogen in plasma 
D)  FDPs 
E)  All of the above

Question 4

Which of the following is/are an example(s) of plasminogen activators?

Accepted Answer

A)  Urokinase 
B)  Streptokinase 
C)  Staphylokinase 
D)  TPA 
E)  All of the above 
A)  Urokinase 
B)  Streptokinase 
C)  Staphylokinase 
D)  TPA 
E)  All of the above

Question 5

DIC due to direct activation of factor VII seen after massive injury results from:

Accepted Answer

A)  Release of tissue thromboplastin 
B)  Release of calcium 
C)  Plasminogen activation 
D)  Thrombo-thrombomodulin complex 
E)  None of the above 
A)  Release of tissue thromboplastin 
B)  Release of calcium 
C)  Plasminogen activation 
D)  Thrombo-thrombomodulin complex 
E)  None of the above

Question 6

What is meant by primary fibrinolysis?

Accepted Answer

A)  Thrombin is formed without coagulation taking place. 
B)  Plasmin is formed without coagulation taking place. 
C)  Formation of plasmin with evidence of coagulation 
D)  Formation of thrombin with evidence of coagulation 
E)  None of the above 
A)  Thrombin is formed without coagulation taking place. 
B)  Plasmin is formed without coagulation taking place. 
C)  Formation of plasmin with evidence of coagulation 
D)  Formation of thrombin with evidence of coagulation 
E)  None of the above

Question 7

At concentration greater than 100 µg/mL, the FDPs are capable of:

Accepted Answer

A)  Inhibiting platelet aggregation and release 
B)  Enhancing platelet aggregation and release 
C)  Enhancing platelet adhesiveness and release 
D)  Inhibiting platelet adhesiveness and release 
E)  None of the above 
A)  Inhibiting platelet aggregation and release 
B)  Enhancing platelet aggregation and release 
C)  Enhancing platelet adhesiveness and release 
D)  Inhibiting platelet adhesiveness and release 
E)  None of the above

Question 8

Therapy in DIC is directed at:

Accepted Answer

A)  Treatment of the underlying pathologic stimulus 
B)  Removal of the underlying pathologic stimulus 
C)  Maintenance of blood volume and hemostatic function 
D)  All of the above 
E)  None of the above 
A)  Treatment of the underlying pathologic stimulus 
B)  Removal of the underlying pathologic stimulus 
C)  Maintenance of blood volume and hemostatic function 
D)  All of the above 
E)  None of the above

Question 9

F1F1F1S1F1F1F102-Anti-plasmin inhibitor irreversibly binds to the __________ binding site on plasmin in a 1:1 molar ratio.

Accepted Answer

A)  Glutamic acid 
B)  Valine 
C)  Arginine 
D)  Lysine 
E)  None of the above 
A)  Glutamic acid 
B)  Valine 
C)  Arginine 
D)  Lysine 
E)  None of the above

Question 10

Which of the following procedures or disease states is/are associated with mechanisms of primary fibrinolysis?

Accepted Answer

A)  Urologic procedures 
B)  Metastatic prostatic carcinoma 
C)  Cirrhosis 
D)  Cardiopulmonary bypass surgery 
E)  All of the above 
A)  Urologic procedures 
B)  Metastatic prostatic carcinoma 
C)  Cirrhosis 
D)  Cardiopulmonary bypass surgery 
E)  All of the above

Question 11

Which laboratory test differentiates primary fibrinolysis from DIC?

Accepted Answer

A)  Platelet count 
B)  PT 
C)  APTT 
D)  TT 
E)  None of the above 
A)  Platelet count 
B)  PT 
C)  APTT 
D)  TT 
E)  None of the above

Question 12

Which substance forms a complex with protein C in the inhibition of activated factors V and VIII?

Accepted Answer

A)  Protein S 
B)  Urokinase 
C)  Tissue plasminogen activator (TP
A)  
D)  Kallikrein 
E)  None of the above 
A)  Protein S 
B)  Urokinase 
C)  Tissue plasminogen activator (TP
A)  
D)  Kallikrein 
E)  None of the above

Question 13

Which term refers to a condition of DIC in which active hemorrhage is evident and the consumption of coagulation factors and platelets exceeds the capacity to increase the synthesis of these components?

Accepted Answer

A)  Decompensated 
B)  Compensated 
C)  Hypercoagulability 
D)  All of the above 
E)  None of the above 
A)  Decompensated 
B)  Compensated 
C)  Hypercoagulability 
D)  All of the above 
E)  None of the above

Question 14

The pathophysiologic effect of DIC is reflective of the balance between:

Accepted Answer

A)  Fibrin deposition 
B)  Fibrinolysis 
C)  Action of thrombin 
D)  Action of plasmin 
E)  All of the above 
A)  Fibrin deposition 
B)  Fibrinolysis 
C)  Action of thrombin 
D)  Action of plasmin 
E)  All of the above

Question 15

Exogenous streptokinase is a product of __________.

Accepted Answer

A)  Gamma-hemolytic streptococci 
B)  Alpha-hemolytic streptococci 
C)  Beta-hemolytic streptococci 
D)  Viridans streptococci 
E)  None of the above 
A)  Gamma-hemolytic streptococci 
B)  Alpha-hemolytic streptococci 
C)  Beta-hemolytic streptococci 
D)  Viridans streptococci 
E)  None of the above

Question 16

Which fibrinogen degradation product (FDP) fragment is capable of clotting?

Accepted Answer

A)  X 
B)  D 
C)  E 
D)  Y 
E)  None of the above 
A)  X 
B)  D 
C)  E 
D)  Y 
E)  None of the above

Question 17

Plasminogen is synthesized in the __________.

Accepted Answer

A)  Liver 
B)  Kidney 
C)  Spleen 
D)  Bone marrow 
E)  None of the above 
A)  Liver 
B)  Kidney 
C)  Spleen 
D)  Bone marrow 
E)  None of the above

Question 18

Which diffuse pathologic form of coagulation results from an accentuated coagulation response leading to consumption of coagulation factors and platelets with subsequent fibrin thrombi throughout the microcirculation as well as the site of endothelial damage?

Accepted Answer

A)  Fibrinolysis 
B)  Disseminated intravascular coagulation (DI
C)  
C)  Coagulation 
D)  All of the above 
E)  None of the above 
A)  Fibrinolysis 
B)  Disseminated intravascular coagulation (DI
C)  
C)  Coagulation 
D)  All of the above 
E)  None of the above

Question 19

Elevated FDPs have which of the following effects?

Accepted Answer

A)  Prolong thrombin time 
B)  Form soluble complexes with fibrin 
C)  Inhibit platelet function 
D)  None of the above 
E)  All of the above 
A)  Prolong thrombin time 
B)  Form soluble complexes with fibrin 
C)  Inhibit platelet function 
D)  None of the above 
E)  All of the above

Question 20

Which form of plasminogen is more readily converted to active plasmin by plasminogen activators?

Accepted Answer

A)  Glu-plasminogen 
B)  Val-plasminogen 
C)  Lys-plasminogen 
D)  Arg-plasminogen 
E)  None of the above 
A)  Glu-plasminogen 
B)  Val-plasminogen 
C)  Lys-plasminogen 
D)  Arg-plasminogen 
E)  None of the above

Exam 27: Interaction of the Fibrinolytic, Coagulation, and Kinin Systems; Disseminated Intravascular Coagulation; and Related Pathology

The peripheral blood smear in DIC resembles that of:

The primary physiologic inhibitor of plasmin in-vivo is __________.

Which of the following are laboratory tests to detect the action of plasmin on fibrin/fibrinogen?

Which of the following is/are an example(s) of plasminogen activators?

DIC due to direct activation of factor VII seen after massive injury results from:

What is meant by primary fibrinolysis?

At concentration greater than 100 µg/mL, the FDPs are capable of:

Therapy in DIC is directed at:

2-Anti-plasmin inhibitor irreversibly binds to the __________ binding site on plasmin in a 1:1 molar ratio.

Which of the following procedures or disease states is/are associated with mechanisms of primary fibrinolysis?

Which laboratory test differentiates primary fibrinolysis from DIC?

Which substance forms a complex with protein C in the inhibition of activated factors V and VIII?

Which term refers to a condition of DIC in which active hemorrhage is evident and the consumption of coagulation factors and platelets exceeds the capacity to increase the synthesis of these components?

The pathophysiologic effect of DIC is reflective of the balance between:

Exogenous streptokinase is a product of __________.

Which fibrinogen degradation product (FDP) fragment is capable of clotting?

Plasminogen is synthesized in the __________.

Which diffuse pathologic form of coagulation results from an accentuated coagulation response leading to consumption of coagulation factors and platelets with subsequent fibrin thrombi throughout the microcirculation as well as the site of endothelial damage?

Elevated FDPs have which of the following effects?

Which form of plasminogen is more readily converted to active plasmin by plasminogen activators?

Morphology of Human Blood and Marrow Cells: Hematopoiesis

Bone Marrow

The Red Blood Cell: Structure and Function

Anemia: Diagnosis and Clinical Considerations

Evaluation of Red Blood Cell Morphology and Introduction to Platelet and White Blood Cell Morphology

Iron Metabolism and Hypochromic Anemias

Megaloblastic Anemias

Aplastic Anemia Including Pure Red Cell Aplasia and Congenital Dyserythropoietic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Introduction to Hemolytic Anemias: Intracorpuscular Defects: I Hereditary Defects of the Red Cell Membrane

Hemolytic Anemias: Intracorpuscular Defects: II Hereditary Enzyme Deficiencies

Hemolytic Anemias: Intracorpuscular Defects: III the Hemoglobinopathies

Hemolytic Anemias: Intracorpuscular Defects: Iv Thalassemia

Hemolytic Anemias: Extracorpuscular Defects

Hypoproliferative Anemia: Anemia Associated With Systemic Diseases

Cell Biology, Disorders of Neutrophils, Infectious Mononucleosis, and Reactive Lymphocytosis

Introduction to Leukemia and the Acute Leukemias

Chronic Myeloproliferative Disorders I: Chronic Myelogenous Leukemia

Chronic Myeloproliferative Disorders Ii: Polycythemia Vera, Essential Thrombocythemia, and Idiopathic Myelofibrosis

Myelodysplastic Syndromes

Chronic Lymphocytic Leukemia and Related Lymphoproliferative Disorders

The Lymphomas

Multiple Myeloma and Related Plasma Cell Disorders

Lipid Lysosomal Storage Diseases and Histiocytosis

Introduction to Hemostasis

Disorders of Primary Hemostasis: Quantitative and Qualitative Platelet Disorders and Vascular Disorders

Disorders of Plasma Clotting Factors

Introduction to Thrombosis and Anticoagulant Therapy

Quality Control in the Hematology Laboratory

Body Fluid Examination: the Qualitative, Quantitative, and Morphologic Analysis of Serous, Cerebrospinal, and Synovial Fluids

Hematology Methods

Principles of Automated Differential Analysis

Coagulation Procedures

Applications of Flow Cytometry to Hematology and Hemostasis

Molecular Diagnostic Techniques in Hematopathology

Special Stainscytochemistry

Filters

₂-Anti-plasmin inhibitor irreversibly binds to the __________ binding site on plasmin in a 1:1 molar ratio.